Literature DB >> 18647326

Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis.

C Boyd1, M J Smith, L Kluwe, A Balogh, M Maccollin, S R Plotkin.   

Abstract

Schwannomatosis is a third major form of neurofibromatosis that has recently been linked to mutations in the SMARCB1 (hSnf5/INI1) tumor suppressor gene. We analyzed the coding region of SMARCB1 by direct sequencing and multiplex ligation-dependent probe amplification (MLPA) in genomic DNA from 19 schwannomatosis kindreds. Microsatellite markers in the SMARCB1 region were developed to determine loss of heterozygosity (LOH) in associated tumors. We detected four alterations in conserved splice acceptor or donor sequences of exons 3, 4 and 6. Two alterations that likely affect splicing were seen in introns 4 and 5. An additional four alterations of unclear pathogenicity were found to segregate on the affected allele in eight families including two non-conservative missense alterations in three families. No constitutional deletions or duplications were detected by MLPA. Nine of 13 tumors examined showed partial LOH of the SMARCB1 region consistent with 'second hits.' Alterations were detected in tumors both with and without somatic NF2 gene changes. These findings support the hypothesis that SMARCB1 is a tumor suppressor for schwannomas in the context of familial disease. Further work is needed to determine its role in other multiple and single tumor syndromes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647326     DOI: 10.1111/j.1399-0004.2008.01060.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  56 in total

1.  Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with "neuroblastoma-like" schwannomatosis and a novel germline SMARCB1 mutation.

Authors:  Jodi M Carter; Carolyn O'Hara; George Dundas; Dawna Gilchrist; Mark S Collins; Katherine Eaton; Alexander R Judkins; Jaclyn A Biegel; Andrew L Folpe
Journal:  Am J Surg Pathol       Date:  2012-01       Impact factor: 6.394

Review 2.  Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis.

Authors:  Till Holsten; Susanne Bens; Florian Oyen; Karolina Nemes; Martin Hasselblatt; Uwe Kordes; Reiner Siebert; Michael C Frühwald; Reinhard Schneppenheim; Ulrich Schüller
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

3.  Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.

Authors:  Camille Louvrier; Eric Pasmant; Audrey Briand-Suleau; Joëlle Cohen; Patrick Nitschké; Juliette Nectoux; Lucie Orhant; Cécile Zordan; Cyril Goizet; Stéphane Goutagny; Dominique Lallemand; Michel Vidaud; Dominique Vidaud; Michel Kalamarides; Béatrice Parfait
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

4.  Congenital anomalies and rhabdoid tumor associated with 22q11 germline deletion and somatic inactivation of the SMARCB1 tumor suppressor.

Authors:  George Toth; Claudia B Zraly; Tricia L Thomson; Carolyn Jones; Shawn Lapetino; Jonathan Muraskas; Jiwang Zhang; Andrew K Dingwall
Journal:  Genes Chromosomes Cancer       Date:  2011-03-15       Impact factor: 5.006

5.  Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome.

Authors:  Yoshinori Tsurusaki; Nobuhiko Okamoto; Hirofumi Ohashi; Tomoki Kosho; Yoko Imai; Yumiko Hibi-Ko; Tadashi Kaname; Kenji Naritomi; Hiroshi Kawame; Keiko Wakui; Yoshimitsu Fukushima; Tomomi Homma; Mitsuhiro Kato; Yoko Hiraki; Takanori Yamagata; Shoji Yano; Seiji Mizuno; Satoru Sakazume; Takuma Ishii; Toshiro Nagai; Masaaki Shiina; Kazuhiro Ogata; Tohru Ohta; Norio Niikawa; Satoko Miyatake; Ippei Okada; Takeshi Mizuguchi; Hiroshi Doi; Hirotomo Saitsu; Noriko Miyake; Naomichi Matsumoto
Journal:  Nat Genet       Date:  2012-03-18       Impact factor: 38.330

6.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors:  Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

Review 7.  Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome.

Authors:  William D Foulkes; Junne Kamihara; D Gareth R Evans; Laurence Brugières; Franck Bourdeaut; Jan J Molenaar; Michael F Walsh; Garrett M Brodeur; Lisa Diller
Journal:  Clin Cancer Res       Date:  2017-06-15       Impact factor: 12.531

8.  SMARCB1/INI1 alterations and hepatoblastoma: another extrarenal rhabdoid tumor revealed?

Authors:  Pierre Russo; Jaclyn A Biegel
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

9.  What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.

Authors:  Joseph L Kissil; Jaishri O Blakeley; Rosalie E Ferner; Susan M Huson; Michel Kalamarides; Victor-Felix Mautner; Frank McCormick; Helen Morrison; Roger Packer; Vijaya Ramesh; Nancy Ratner; Katherine A Rauen; David A Stevenson; Kim Hunter-Schaedle; Kathryn North
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

10.  Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas.

Authors:  Arkadiusz Piotrowski; Jing Xie; Ying F Liu; Andrzej B Poplawski; Alicia R Gomes; Piotr Madanecki; Chuanhua Fu; Michael R Crowley; David K Crossman; Linlea Armstrong; Dusica Babovic-Vuksanovic; Amanda Bergner; Jaishri O Blakeley; Andrea L Blumenthal; Molly S Daniels; Howard Feit; Kathy Gardner; Stephanie Hurst; Christine Kobelka; Chung Lee; Rebecca Nagy; Katherine A Rauen; John M Slopis; Pim Suwannarat; Judith A Westman; Andrea Zanko; Bruce R Korf; Ludwine M Messiaen
Journal:  Nat Genet       Date:  2013-12-22       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.